Physician profile
Michael C Yim
NPI 1669816864
$161,240.57
in general payments reported to CMS, 2019-2025
27 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,618 · 2020: $23K · 2021: $40K · 2022: $23K · 2023: $4,055 · 2024: $26K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Food and Beverage: $5,170 · Travel and Lodging: $4,481 · Consulting Fee: $3,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,995.00 |
| Food and Beverage | $5,170.31 |
| Travel and Lodging | $4,480.58 |
| Consulting Fee | $3,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $59,337.80 | 2019-2021 | |
| Alcon Vision LLC | $46,555.25 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Sight Sciences, INC. | $44,995.54 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ivantis, INC | $3,586.81 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $2,130.64 | 2019 | |
| Glaukos Corporation | $810.96 | 2019-2025 | Idose, Idosetr |
| Abbvie INC. | $752.29 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $740.87 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $324.05 | 2019-2024 | |
| Allergan, INC. | $306.03 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $261.46 | 2022-2025 | Vyzulta, Envista Mx60 Iol, Miebo |
| Eyevance Pharmaceuticals LLC | $198.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $160.48 | 2020-2025 | Shingrix, Arexvy |
| New World Medical,INC. | $144.98 | 2019 | |
| Shire North American Group INC | $133.07 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $123.83 | 2022-2025 | Tyrvaya, Ryzumvi |
| Regeneron Healthcare Solutions, INC. | $116.38 | 2019 | |
| Amgen INC. | $111.32 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $86.56 | 2019-2022 | |
| Hoffmann-La Roche Limited | $81.20 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $67.06 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $57.28 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $54.35 | 2019-2022 | |
| Horizon Therapeutics Plc | $40.17 | 2022-2023 | Tepezza |
| Beaver-Visitec International, INC. | $31.45 | 2019 | |
| Welch Allyn | $19.41 | 2021 | |
| Harrow Eye, LLC | $12.94 | 2023 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.